Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone for Prevention of Episodic Migraine
NCT04151472Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of idebenone in episodic migraine (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline of 4-week migraine headache days (MHD) at 12 weeks. Started Dec 2021; status: recruiting.
02
Drugs
idebenone
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT04151472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151472.